- Home
- ADVB vs MYNZ Comparison
ADVB vs MYNZ Comparison
Compare ADVB & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVB
- MYNZ
- Stock Information
- Founded
- ADVB 2014
- MYNZ 2021
- Country
- ADVB United States
- MYNZ Germany
- Employees
- ADVB N/A
- MYNZ N/A
- Industry
- ADVB Medical Specialities
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ADVB Health Care
- MYNZ Health Care
- Exchange
- ADVB Nasdaq
- MYNZ Nasdaq
- Market Cap
- ADVB 9.1M
- MYNZ 7.9M
- IPO Year
- ADVB 2025
- MYNZ 2021
- Fundamental
- Price
- ADVB $0.42
- MYNZ $1.61
- Analyst Decision
- ADVB
- MYNZ Buy
- Analyst Count
- ADVB 0
- MYNZ 2
- Target Price
- ADVB N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- ADVB 371.2K
- MYNZ 107.2K
- Earning Date
- ADVB 11-03-2025
- MYNZ 10-21-2025
- Dividend Yield
- ADVB N/A
- MYNZ N/A
- EPS Growth
- ADVB N/A
- MYNZ N/A
- EPS
- ADVB N/A
- MYNZ N/A
- Revenue
- ADVB N/A
- MYNZ $893,991.00
- Revenue This Year
- ADVB N/A
- MYNZ $26.06
- Revenue Next Year
- ADVB N/A
- MYNZ $4.97
- P/E Ratio
- ADVB N/A
- MYNZ N/A
- Revenue Growth
- ADVB N/A
- MYNZ N/A
- 52 Week Low
- ADVB $0.34
- MYNZ $1.30
- 52 Week High
- ADVB $4.10
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- ADVB N/A
- MYNZ 44.61
- Support Level
- ADVB N/A
- MYNZ $1.70
- Resistance Level
- ADVB N/A
- MYNZ $1.79
- Average True Range (ATR)
- ADVB 0.00
- MYNZ 0.11
- MACD
- ADVB 0.00
- MYNZ -0.00
- Stochastic Oscillator
- ADVB 0.00
- MYNZ 3.33
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.